

LMNA-Related Disorders

Indications for Ordering

To confirm a clinical diagnosis of a *LMNA*-related disorder

- Hutchinson-Gilford progeria syndrome (HGPS)
- Emery-Dreifuss muscular dystrophy type 2 (EDMD2)
- Limb-Girdle muscular dystrophy 1B (LGMD1B)
- Charcot-Marie-Tooth 2B1 (CMT2B1)
- Familial partial lipodystrophy, Dunnigan type (FPLD)
- *LMNA*-related dilated cardiomyopathy (DCM)
- Mandibulo-acral dysplasia (MAD)
- Atypical Werner syndrome (WS)
- Restrictive dermopathy (RD)
- Other, intermediate phenotypes

Test Description

- Polymerase chain reaction (PCR) followed by bidirectional sequencing of all coding regions and intron/exon boundaries of the *LMNA* gene
- Multiplex ligation-dependent probe amplification (MLPA) to detect large *LMNA* deletions/duplications

Tests to Consider

Primary tests

[LMNA-Related Disorders \(LMNA\) Sequencing 2004543](#)

- Confirm suspected laminopathy caused by *LMNA* variants, including HGPS, EDMD2, LGMD1B, CMT2B1, FPLD, DCM, MAD, WS, or RD

[LMNA-Related Disorders \(LMNA\) Deletion/Duplication 2004539](#)

- Confirm suspected laminopathy caused by *LMNA* variants, including EDMD2, LGMD1B, or DCM

Related test

[Familial Mutation, Targeted Sequencing 2001961](#)

- Useful when a pathogenic familial variant identifiable by sequencing is known

Disease Overview

Prevalence and/or incidence

- HGPS – 1/8 million births
- DCM – ~1/2,500 births
 - Familial – 30-60%
 - *LMNA* gene variants cause ~8% of familial cases
- Incidence of other *LMNA*-associated disorders – unknown

Symptoms

- Variants in the *LMNA* gene cause a broad range of clinical diseases collectively termed laminopathies
- Clinical findings are highly variable
- See table

Genetics

Genes – *LMNA*

Inheritance – see table

Penetrance – varies by syndrome

Structure/function

- Composed of 12 exons
- *LMNA* encodes isoforms A and C of the lamin protein
 - Structural component of the nuclear membrane
 - Anchors heterochromatin to the inner nuclear membrane

Variants

- Alternative splicing of the *LMNA* gene produces two proteins (lamin A and C)
- Variants occur throughout the gene
 - Predominantly missense
 - p.G608G variant in exon 11
 - Present in all individuals with HGPS

Test Interpretation

Sensitivity/specificity

- Clinical sensitivity – dependent on the specific *LMNA*-related disorder
- Analytic sensitivity
 - Sequencing – 99%
 - MLPA – 90%
- Analytical specificity
 - Sequencing – 99%
 - MLPA – 98%

Results

- Positive – single pathogenic *LMNA* variant detected
 - Consistent with diagnosis of an autosomal dominant laminopathy
 - May indicate carrier status for an autosomal recessive *LMNA*-related disorder
- Negative – *LMNA* variant not detected
 - Lack of detection decreases the probability of, but does not exclude, the possibility of a laminopathy
- Gene variants of uncertain significance may be detected by *LMNA* sequencing

Limitations

- Diagnostic errors can occur due to rare sequence variations
- Not determined or evaluated
 - Some regulatory region variants
 - Deep intronic variants
 - Breakpoints of large deletions/duplications
 - Variants in genes other than *LMNA*
- Large deletions/duplications in exon 8 may not be detected

<i>LMNA</i> -Related Disorders: Clinical Features and Inheritance Patterns		
Disease	Clinical Features	Inheritance
HGPS	<ul style="list-style-type: none"> • Symptoms that resemble accelerated aging, profound failure to thrive, characteristic facies, alopecia, joint degeneration, growth retardation • Age of onset – ~1 year with average life expectancy of 13 years 	All affected individuals carry a de novo, dominant p.Gly608Gly variant in <i>LMNA</i> exon 11
EDMD2	<ul style="list-style-type: none"> • Joint contractures, progressive muscle weakness and wasting, cardiac disease with conduction defects and arrhythmias • Age of onset – variable 	Autosomal dominant most common; autosomal recessive cases are very rare
LGMD1B	<ul style="list-style-type: none"> • Progressive proximal lower limb weakness and atrioventricular cardiac conduction complications • Age of onset – birth to adulthood, with 50% in childhood 	Autosomal dominant
CMT2B1	<ul style="list-style-type: none"> • Symmetrical distal muscle weakness and atrophy, depressed or absent tendon reflexes • Age of onset – ~14 years 	Autosomal recessive; very rare
FPLD	<ul style="list-style-type: none"> • Progressive loss of subcutaneous fat from the extremities and excess fat accumulation on the face and neck • Age of onset – postpubescent 	Autosomal dominant
DCM	<ul style="list-style-type: none"> • Progressive ventricular dilation and impaired systolic function leading to congestive heart failure • Age of onset – usually adults between 4th and 6th decade 	Autosomal dominant
MAD	<ul style="list-style-type: none"> • Postnatal growth retardation, craniofacial and skeletal anomalies, mottled cutaneous pigmentation • Age of onset – ~4 years 	Autosomal recessive
Atypical WS	<ul style="list-style-type: none"> • Progeroid syndrome with features of partial alopecia, premature aging, short stature, hypogonadism, osteoporosis, premature atherosclerosis, weak voice, cataracts • Age of onset – ~13 years 	Autosomal dominant
RD	<ul style="list-style-type: none"> • Skin tightness causes fetal akinesia or hypokinesia deformation sequence – lethal • Age of onset – fetal with live born children usually dying in 1st week 	Rarely due to variant of <i>LMNA</i> ; reported cases have a de novo, autosomal dominant variant